PALVELLA THERAPEUTICS, INC. annual report, FY2018

Business context and reporting period

Pieris Pharmaceuticals, Inc. (Nasdaq: PIRS) filed this Form 10-K for the fiscal year ended December 31, 2018; it is an annual report, not a standalone fourth-quarter report. The request metadata names “Pavella Therapeutics, Inc.,” but the filing identifies the registrant as Pieris Pharmaceuticals, Inc.

Pieris is a clinical-stage biotechnology company developing Anticalin-based medicines. Its principal clinical programs were PRS-060 for asthma, PRS-343 for HER2-positive cancers, and PRS-080 for anemia associated with chronic kidney disease. The company had no approved products and no product-sales revenue.

Financial performance and liquidity

Revenue consisted chiefly of collaboration and license income, not product sales. License-fee revenue was $26.7 million, research and development services revenue $1.8 million, and milestone revenue $0.6 million. No gross margin is reported for product sales.

At year-end, cash and cash equivalents were $74.9 million and short-term investments were $53.2 million, totaling approximately $128.1 million in cash, cash equivalents, and investments. Current assets were $135.4 million and current liabilities $48.1 million. Total liabilities were $101.4 million, including $88.9 million of deferred revenue; the balance sheet presents no separate debt balance. The company reported $6.5 million of loans among historical funding sources.

Operating cash outflow was $1.1 million, compared with inflow of $49.8 million in 2017. The 2018 figure reflected substantial partner receipts offset by operating spending, while investing activity included $117.6 million of investment purchases and $110.4 million of maturities and sales. Financing cash inflow was $48.5 million, largely from the February 2018 public offering, which generated $47.6 million net proceeds before approximately $0.4 million of offering expenses.

Material changes versus the prior comparable period

• Revenue increased $3.8 million, or approximately 15%, as collaboration activity and license-fee recognition rose; milestone revenue fell $12.0 million, mainly because a $12.5 million AstraZeneca milestone had been recognized in 2017.
• R&D expense rose $19.2 million, or approximately 86%, reflecting higher immuno-oncology and respiratory program costs, manufacturing, clinical activity, and personnel costs.
• Net loss increased $9.1 million, or approximately 52%, as expense growth substantially exceeded revenue growth.
• Cash and cash equivalents rose to $74.9 million from $37.9 million, while investments totaled $53.2 million at year-end. Working capital was approximately $87.3 million.
• Non-operating results improved by approximately $5.8 million, primarily due to foreign-currency transaction gains in 2018 versus losses in 2017 and higher interest income.

Outlook, risks, contingencies, and unusual items

• Management expected existing cash, cash equivalents, and investments to fund operations and capital needs for at least 12 months from the financial statements’ issuance. It expects continued losses and significant development spending; no specific financial guidance was provided.
• PRS-060’s phase 1 single-ascending-dose study was reported safe and well tolerated; its multiple-dose study was ongoing. Pieris expected to report study data at future medical meetings. AstraZeneca was to fund and lead later development, subject to Pieris’s options.
• PRS-343 monotherapy and combination studies with atezolizumab were ongoing, with comprehensive data expected in 2019. PRS-080 phase 2a dosing was completed in 2018, with full data expected in 2019 and an ASKA option decision to follow. Pieris planned to file an IND for PRS-344 in the second half of 2019.
• In January 2019, after year-end, Pieris exchanged 5.0 million common shares held by Biotechnology Value Fund for 5,000 Series B convertible preferred shares, convertible into 5.0 million common shares subject to ownership limits.
• Pieris recorded approximately $2.3 million of additional expected obligations related to its TUM license, for amounts due in 2019 for prior sublicensing activity; amended license terms remained under discussion.
• The company entered a long-term lease for new German laboratory and office space. Base rent for the initial space is approximately $0.2 million monthly, and total disclosed minimum operating-lease payments were $36.0 million as of year-end.
• Management reported that disclosure controls and internal control over financial reporting were not effective at December 31, 2018, citing a material weakness in the income-tax provision process. A separate 2017 close-process weakness was reported as remediated. The auditor’s opinion on the financial statements was unqualified; the auditor did not opine on internal control effectiveness.
• Key risks include clinical and regulatory failure, dependence on partners and contract manufacturers, need for additional capital, competition, intellectual-property protection, foreign-exchange exposure, and execution of the planned facility move. The filing reported no material legal proceedings as of its filing date.

Important facts for investors to verify

• Confirm the registrant identity: this filing is for Pieris Pharmaceuticals, Inc., not the company named in the request metadata.
• Review the detailed cash-flow statement and cash runway assumptions, including the timing and availability of collaboration receipts and investment maturities.
• Track clinical data and milestones for PRS-060, PRS-343, PRS-344, and PRS-080, and confirm partner decisions and funding responsibilities.
• Assess whether the income-tax control weakness is remediated and monitor the effects of adopting new revenue-recognition rules.
• Evaluate the dilution and ownership effects of preferred-stock conversion, outstanding options, and potential future capital raises.
• Check the timing, occupancy, and total cost of the Hallbergmoos lease and facility relocation.